Adoption of Biosimilars: Prescribers, Pharmacy and Payer Perspectives
Adoption of Biosimilars: Prescribers, Pharmacy and Payer Perspectives
FACULTY
Steven D. Lucio, PharmD, BCPSSenior Director Clinical Solutions and Pharmacy Program DevelopmentVizientIrving, Texas
EDITORIAL SUPPORT
Debra Gordon, MSPresidentGordonSquared, IncHighland Park, Illinois
Disclosures
Steven Lucio, PharmD, BCPS, has the following relevant financial relationships with commercial interests to disclose.
Employment: Vizient
The following contributors have no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education Planning Staff— David Heckard; Maryjo Dixon, RPh; Donna Fausak; and Tara DeLorenzo
Specialty Pharmacy Times Editorial Staff—Davy James
An anonymous peer reviewer was part of the content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Objectives
At the completion of this activity, the participant will be able to:
- Explain the development and approval process for biosimilars
- Identify how biosimilars differ from small-molecule generics
- Examine the challenges to clinicians in adopting biosimilars
- Illustrate potential barriers to physician and patient uptake of biosimilars
- Determine how formulary and clinical adoption of biosimilar agents will impact managed care
Target audience: Pharmacists
Type of activity: Application
Release date: April 12, 2016
Expiration date: April 12, 2017
Estimated time to complete activity: 1.5 hours
Fee: This lesson is offered for free at www.pharmacytimes.org.
Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-15-130-H01-P. The activity is available for CE credit through April 12, 2017.
